Cardiovascular effects of HAART in infants and children of HIV-infected mothers

Cardiovascular Toxicology

Volumn 4, Issue 3, 2004, Pages 271-279

  Zareba, Karolina M ^a   Lavigne, Jill E ^b   Lipshultz, Steven E ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cardiomyopathy; Dyslipidemia; HAART; HIV; Mitochondrial toxicity; Prophylactic antiretroviral therapy.

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ATHEROSCLEROSIS; BACTERIAL INFECTION; BRAIN DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD; DISEASE SEVERITY; DRUG EFFECT; DYSLIPIDEMIA; EARLY DIAGNOSIS; EXPERIENCE; GLUCOSE INTOLERANCE; HEART DILATATION; HEART PROTECTION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; ISCHEMIC HEART DISEASE; MITOCHONDRIAL TOXICITY; MOTHER CHILD RELATION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; TACHYCARDIA; VERTICAL TRANSMISSION; WASTING SYNDROME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD, PRESCHOOL; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEART DEFECTS, CONGENITAL; HEART DISEASES; HIV INFECTIONS; HUMANS; INFANT; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 6044260105     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:3:271     Document Type: Review

References (44)

1. AIDS Epidemic Update December 2002. http://www.unaids.org. Accessed November 15, 2003.
2. Mofenson, L.M. and McIntyre, J.A. (2000). Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 355:2237-2244.
3. Lipshultz, S.E., Chanock, S., Sanders, S.P., Colan, S.D., Perez-Atayde, A., and McIntosh, K. (1989). Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am. J. Cardiol. 63:1489-1497.
4. Lipshultz, S.E. (1998). Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med. 339:1153-1155.
5. 2 HIV) Study Group. Circulation 97:1246-1256.
6. 2 HIV) Study Group. Circulation 102:1542-1548.
7. 2 HIV): a cohort study. Lancet 360:368-373.
8. 2 HIV study. J. Pediatr. 141:327-334.
9. Al-Attar, L., Orav, E.J., Exil, V., Vlach, S.A., and Lipshultz, S.E. (2003). Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J. Am. Coll. Cardiol. 41:1598-1605.
10. 2 HIV Multicenter Study. J. Am. Coll. Cardiol., in press.
11. Hornberger, L.K., Lipshultz, S.E., Easley, K.A., Colan, S.D., Schwartz, M., Kaplan, S., et al. (2000). Cardiac structure and function in fetuses of mothers infected with HIV: the prospective PCHIV multicenter study. Am. Heart J. 140:575-584.
12. Felker, G.M., Thompson, R.E., Hare, I.M., Hruban, R.H., Clemetson, D.E., Howard, D.L., et al. (2000). Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342:1077-1084.
13. Lipshultz, S.E., Fisher, S.D., Lai, W.W., and Miller, T.L. (2003). Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17:S96-S122.
14. Heidenreich, P.A., Eisenberg, M.J., Kee, L.L., Somelofski, C.A., Hollander, H., Schiller, N.B., et al. (1995). Pericardial effusion in AIDS. Incidence and survival. Circulation 92:3229-3234.
15. Mesa, R.A., Edell, E.S., Dunn, W.F., and Edwards, W.D. (1998). Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin. Proc. 73:37-45.
16. Ienson, H.B. and Pollock, B.H. (1998). Cardiac cancers in HIV-infected patients, in Cardiology in AIDS (Lipshultz, S.E., ed.), Chapman and Hall, New York, pp. 255-263.
17. Dube, M.P., Sprecher, D., Henry, W.K., Aberg, I.A., Torriani, F.J., Hodis, H.N., et al. (2000). Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31:1216-1224.
18. Maggi, P., Serio, G., Epifani, G., Florentine, G., Saracino, A., Fico, C., et al. (2000). Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14:F123-F128.
19. Danner, S.A., Carr, A., Leonard, J.M., Lehman, L.M., Gudiol, F., Gonzales, J., et al. (1995). A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. 333:1528-1533.
20. Purnell, J.Q., Zambon, A., Knopp, R.H., Pizzuti, D.J., Achari, R., Leonard, J.M., et al. (2000). Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57.
21. Friis-Moller, N., Sabin, C.A., Weber, R., d'Arminio Monforte, A., El-Sadr, W.M., Reiss, P., et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349:1993-2003.
22. Schambelan, M., Benson, C.A., Carr, A., Currier, J.S., Dube, M.P., Gerber, J.G., et al. (2002). Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31:257-275.
23. Hoffmann, C. and Jaeger, H. (2001). Cardiology and AIDS-HAART and the consequences. Ann. NY Acad. Sci. 946:130-144.
24. Lipshultz, S.E., Fisher, S.D., Lai, W.W., and Miller, T.L. (2001). Cardiovascular monitoring and therapy for HIV-infected patients. Ann. NY Acad. Sci. 946:236-273.
25. Scevola, D., Di Matteo, A., Lanzarini, P., Uberti, F., Scevola, S., Bernini, V., et al. (2003). Effects of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17:8123-8129.
26. Lindegren, M.L., Byers, R.H. Jr., Thomas, P., Davis, S.F., Caldwell, B., Rogers, M., et al. (1999). Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 282:531-538.
27. Connor, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M.J., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331:1173-1180.
28. Mofenson, L.M. and Munderi, P. (2002). Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J. Acquir. Immune Defic. Syndr. 30:200-215.
29. Dabis, F., Msellati, P., Meda, N., Welffens-Ekra, C., You, B., Manigart, O., et al. (1999). 6-month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 353:786-792.
30. Shaffer, N., Chuachoowong, R., Mock, P.A., Bhadrakom, C., Siriwasin, W., Young, N.L., et al. (1999). Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 353:773-780.
31. Wiktor, S.Z., Ekpini, E., Karon, J.M., Nkengasong, J., Maurice, C., Severin, S.T., et al. (1999). Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353:781-785.
32. Guay, L.A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C., et al. (1999). Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
33. Brinkman, K., ter Hofstede, H.J.M., Burger, D.M., Smeitink, J.A.M., and Koopmans, P.P. (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 12:1735-1744.
34. Lipshultz, S.E., Giantris, A.L., Lipsitz, S.R., Kimball Dalton, V., Asselin, B.L., Barr, R.D., et al. (2002). Continuous doxorubicin infusion is not cardioprotective: the Dana Farber 91-01 ALL protocol. J. Clin. Oncol. 20:1677-1682.
35. Lewis, W., Haase, C.P., Raidel, S.M., Russ, R.B., Sutliff, R.L., Hoit, B.D., et al. (2001). Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab. Invest. 81:1527-1536.
36. Gerschenson, M., Erhart, S.W., Paik, C.Y., St. Claire, M.C., Nagashima, K., Skopets, B., et al. (2000) Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido- 3′-deoxythymidine. AIDS Res. Hum. Retroviruses 16:635-644.
37. Ewings, E.L., Gerschenson, M., St. Claire, M.C., Nagashima, K., Skopets, B., Harbaugh, S.W., et al. (2000). Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J. Acquir. Immune Defic. Syndr. 24:100-105.
38. Poirier, M.C., Divi, R.L., Al-Harthi, L., Olivero, O.A., Nguyen, V., Walker, B., et al. (2003). Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J. Acquir. Immune Defic. Syndr. 33:175-183.
39. Alimenti, A., Burdge, D.R., Ogilvie, G.S., Money, D.M., and Forbes, J.C. (2003). Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr. Infect. Dis. J. 22:782-789.
40. Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., et al. (1999). Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089.
41. Lipshultz, S.E., Orav, E.J., Sanders, S.P., Hale, A.R., McIntosh, K., and Colan, S.D. (1992). Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N. Engl. J. Med. 327:1260-1265.
42. Lipshultz, S.E., Easley, K.A., Orav, E.J., Kaplan, S., Starc, T.J., Bricker, J.T., et al. (2000). Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N. Engl. J. Med. 343:759-766.
43. Lavigne, J.E., Shearer, W.T., Thompson, B., Orav, E.J., Starc, T.J., Colan, S.D., et al., for the CHAART Study Group (2004). Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. Cardiovascular Toxicology, in press.
44. Harmon, W.G., Dadlani, G.H., Fisher, S.D., and Lipshultz, S.E. (2002). Myocardial and pericardial disease in HIV. Curr. Treat. Options Cardiovasc. Med. 4(6):497-509.